Pharsight

Omegaven patents expiration

OMEGAVEN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(8 months from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(1 year, 4 months from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(1 year, 4 months from now)

Omegaven is owned by Fresenius Kabi Usa.

Omegaven contains Fish Oil Triglycerides.

Omegaven has a total of 3 drug patents out of which 0 drug patents have expired.

Omegaven was authorised for market use on 27 July, 2018.

Omegaven is available in emulsion;intravenous dosage forms.

Omegaven can be used as treatment of parenteral nutrition-associated cholestasis in patients under the age of 12, use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease, treatment of liver disease through nutrition for patients under the age of 12.

The generics of Omegaven are possible to be released after 27 July, 2025.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver dis...

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

OMEGAVEN family patents

Family Patents